Products Overview

Publications -


  1. Virella, G., Wohltmann, H., Sagel, J., Lopes-Virella, M.F.L., Phillips, C.B., Kilpatrick, M., and Colwell, J. 1981. Soluble immune complexes in patients with Diabetes Mellitus: Detection and pathological significance. Diabetologia 21: 189-191.
  2. Tsang, K.Y., Fudenberg, H.H., Pan, J.F., Gnagy, M.J., and Bristow, C.L. 1983. An in vitro study on the effects of isoprinosine on immune responses in cancer patients. Int. J. Immunopharm. 5: 481-493.
  3. Bristow, C.L. and Boackle, R.J. 1986. Role for human serum amyloid P component in immune clearance through interaction with C1q and Fabγ. Mol. Immunol. 23: 1045-1052.
  4. Bristow, C.L. and Marchalonis, J.J. 1989. Solid-phase antigen binding by purified immunoproteins from antigen-specific monoclonal T cell hybridomas. Mol. Immunol. 26: 611-624.
  5. Bristow, C.L., Lyford, L.K., Stevens, D.P., and Flood, P.M. 1991. Elastase is a constituent product of T cells. Biochem. Biophys. Res. Comm. 181: 232-239.
  6. Bristow, C.L. and Flood, P.M. 1993. T cell antigen receptor immune complexes demonstrating biologic and proteolytic activity. Int. Immunol. 5: 79-88.
  7. Bristow, C.L., Fiscus, S.A., Flood, P.M., and Arnold, R.R. 1995. Inhibition of HIV-1 by modification of a host membrane protease. Int.Immunol. 7: 239-249.
  8. Kuller, J.A., Katz, V.L., McCoy, M.C., and Bristow, C.L. 1995. Alpha1-antitrypsin deficiency and pregnancy. Am. J. Perinatology 12: 303-305.
  9. Bristow, C.L. 1996. HIV Fusion. Science 273:1642-1643.
  10. Bristow, C.L., Di Meo, F., and Arnold, R.R. 1998. Specific activity of α1proteinase inhibitor in human serum: Application to insulin-dependent diabetes mellitus. Clin. Immunol. Immunopathol.89: 247-259.
  11. Bristow, C.L. 2000. The two principal viremias of HIV. A comparison of viral and host characteristics. In: Human Retroviral Infection: Immunological and Molecular Theories, (ed. H. Friedman, K. Ugen, M. Bendinelli) Plenum Publishing Corp., New York, NY, pp. 1-16.
  12. Bristow, C.L. 2001. Slow human immunodeficiency virus (HIV) infectivity correlated with low HIV coreceptor levels. Clin Diagn. Lab. Immunol. 8: 932-936.
  13. Bristow, C.L., Patel, H., and Arnold, R.R. 2001. Self antigen prognostic for human immunodeficiency virus disease progression. Clin Diagn. Lab. Immunol. 8: 937-942.
  14. Messmer, D., Jacque, J-M., Santisteban, C., Bristow, C., Han, S.-Y., Villamide-Herrera, L., Mehlhop, E., Marx, P.A., Steinman, R.M., Gettie, A. and Pope, M. 2002. Nef uncouples cytokine and chemokine production from phenotypic maturation in dendritic cells. J.Immunol. 169:4172-4182.
  15. Cogswell, P.C., Kashatus, D.F., Keifer, J.A., Guttridge, D.C., Reuther, J.Y., Bristow, C., Roy, S., Nicholson, D.W., Baldwin, A.S. 2002. NF-kappa B and Ikappa B alpha are found in the mitochondria: Evidence for regulation of mitochondrial gene expression by NF-kappaB. J. Biol. Chem. 278:2963-2968.
  16. Bristow, C.L., Mercatante, D.R., and Kole, R. 2003. HIV-1 preferentially binds receptors co-patched with cell surface elastase. Blood 102:4479-4486.
  17. Bristow, C.L., Wolkowicz, R., Trucy, M., Franklin, A., Di Meo, F., Kozlowski, M.T., Winston R., Arnold, R.R. 2008. NFkB signaling, elastase localization, and phagocytosis differ in HIV-1 permissive and non-permissive U937 clones. J. Immunol. 180: 492-499.
  18. Bristow, C.L., Cortes, J., Mukhtarzad R., Trucy, M., Franklin, A., Romberg, V., Winston, R. 2010. α1Antitrypsin therapy increases CD4+ lymphocytes to normal values in HIV-1 patients. In Soluble Factors Mediating Innate Immune Responses to HIV Infection, (ed. M. Alfano). Bentham Science Publishers, http://www.eurekaselect.com/54309/volume/1
  19. Bristow, C.L., Babayeva, M.A., LaBrunda, M., Mullen, M.P., and Winston, R. 2012. α1Proteinase Inhibitor regulates CD4+ lymphocyte levels and is rate limiting in HIV-1 disease. PLoS ONE 7: e31383.
  20. Bristow, C.L. Babayeva, M.A, Modarresi, R., McArthur, C.P. Kumar, S., Awasom, C., Ayuk, L., Njinda, A., Achu, P., and Winston, R. 2012. The α-test: Rapid Cell-free CD4 Enumeration Using Whole Saliva. J. Vis. Exp. (63), e3999, DOI: 10.3791/3999.







Copyright 2012 | Alpha-1 Biologics Corporation | All Rights Reserved.
Powered By: Palsoftware